ecause enhanced sympathetic tone is major cause of progression of heart failure, a therapeutic target has been management of the sympathetic nerve activity in patients with chronic heart failure. 1, 2 Recently, sleep disturbance has received special attention in the pathogenesis of autonomic imbalance, which is potentially carried over from night into daytime. 3, 4 The autonomic function fluctuates depending on sleep dynamics when non-rapideye movement (REM) sleep is accompanied by an augmentation of parasympathetic tone and a depression of central sympathetic activity. In contrast, REM sleep is characterized by an augmentation of peripheral sympathetic tone, as confirmed by a microneurographic technique. 5.6 Several previous studies have documented a lack of nocturnal reduction in heart rate (HR) in patients with heart failure as a consequence of hemodynamic abnormalities or sleepdisordered breathing. [7] [8] [9] Therefore, one of the mechanisms for sympathoexcitation in heart failure could involve relative predominance of central sympathetic outflow over parasympathetic tone caused by abnormal sleep. Under these conditions, the central inhibition of overnight sympathetic tone could be a potential target for the treatment of chronic heart failure in terms of autonomic balancing.
This study was therefore designed to examine whether central sympathetic inhibition could restore normal sympathovagal balance during sleep in patients with chronic heart failure. Autonomic nervous function fluctuates in a parallel fashion with the REM/non-REM sleep cycle, so-called ultradian rhythm, in which parasympathetic tone is augmented particularly during non-REM sleep. These autonomic variations could be faithfully reflected by HR variation during sleep. 5, 6, 10 To extract autonomic fluctuations related to sleep dynamics, we quantified the ultradian rhythm of the overnight high-frequency (HF) components of HR variability (HRV).
Methods

Subjects
The present study group comprisee 14 patients with stable heart failure (11 men, 3 women, mean age 57±16 years) with left ventricular ejection fraction less than 40%, and 13 age-matched subjects with normal cardiac function (9 men, 4 women, mean age 61±17 years) ( Table 1 ). The New York Heart Association functional class of the heart failure patients was I in 4, II in 5, and III in 5 patients; 5 patients had ischemic heart disease and 9 had dilated cardiomyopathy. Diuretics had been given to 10 patients, angiotensin-converting enzyme inhibitors or angiotensinreceptor antagonists to 12, digoxin to 5, and -blocker to 3. All these medications were continued throughout the study. The control subjects had stable angina pectoris (9), post- Background Abnormal sleep dynamics in patients with heart failure is one of the mechanisms for the relative predominance of central sympathetic outflow over parasympathetic tone. This study was designed to examine whether central sympathoinhibition could improve the sympathovagal imbalance related to rapid-eye-movement (REM)/non-REM ultradian sleep rhythm in these patients.
Methods and Results
Beat-by-beat RR intervals of overnight electrocardiogram were serially subject to power spectral analysis in 14 patients with chronic heart failure and 13 age-matched subjects with normal cardiac function. To assess autonomic sleep dynamics, the ultradian rhythm was extracted from all-night consecutive highfrequency (HF) components of heart rate variability (HRV) before and after administration of an 2-adrenergic agonist, guanfacine. Night-time HRV in heart failure was characterized by an attenuated ultradian rhythm of HFcomponents with a concomitant reduction in averaged HF power. Guanfacine reduced blood pressure, heart rate, and plasma norepinephrine concentrations by 7%, 8%, and 34% (p<0.01), respectively. After guanfacine, HF power rose by 154% (p<0.01) with a prominent augmentation of the all-night ultradian rhythm (+361%, p<0.01).
Conclusions Central sympathoinhibition augments a sleep-related ultradian rhythm of parasympathetic tone, suggesting a potential benefit to autonomic balancing and sleep quality in patients with chronic heart failure. 
Study Protocol
In all patients, overnight electrocardiography (ECG) without polysomnography was performed for serial power spectral analyses of HRV. The next morning a resting blood sample was obtained after 30 min supine rest for measurements of plasma norepinephrine (NE), brain natriuretic peptide (BNP), and aldosterone concentrations, and plasma renin activity. Then, the 14 patients with heart failure were given low-dose guanfacine (0.25 mg), an 2-adrenergic agonist, once daily before sleep as previously reported. 11,12 After a 5-day regimen, the same measurements were repeated. Changes in cardiac size and function were also examined by chest radiography and 2-dimensional (D) echocardiography before and after the treatment.
Overnight Power Spectral Analysis of HRV
ECG signals were recorded with a Holter ECG device (Morpheus, Teijin, Tokyo, Japan) at a sampling frequency of 256 Hz and stored in a memory disk. 13 The beat-by-beat RR interval was identified from each beat and resampled at 4 Hz to produce the same time series as described previously. [14] [15] [16] Across the entire sleep period, spectral analysis with maximum entropy method was applied to sequential 5-min RR intervals every 50 s to evaluate the spectral components of RR-interval variability: the low-frequency components (low-frequency power (LF), 0.04-0.12 Hz), HF components (HF, 0.12-0.5 Hz), total spectral power, and LF/HF. Fig 1 shows the all-night trend in the RR intervals and HFcomponent variability sampled at 0.02 Hz (every 50 s) in a control subject. Because the ultradian rhythm of REM/non-REM sleep cycle examined in our previous study 13 had nearly 90-min interval (0.00018±0.0001 Hz), we again applied the maximum entropy method to the HF components of HRV to extract the oscillatory components ranging from 0.0001 to 0.0003 Hz (Fig 1) . We then quantified the sleep-related parasympathetic oscillation by the spectral power of HF components variability within these spectral ranges (ultradian power).
Statistical Analysis
All data are expressed as mean ± standard deviation. Baseline variables in controls and patients with heart failure were compared using an unpaired t-test. Differences in variables between before and after administration of guanfacine were examined with a paired t-test. The level of statistical significance was set at p<0.05.
Results
Baseline hemodynamic and autonomic variables and effects of guanfacine are summarized in Table 1 . Resting BNP and averaged all-night HR were significantly higher in patients with heart failure than in control subjects. All-night spectral power of HRV and the ultradian power of HFcomponent variability were markedly decreased in patients with heart failure. These patients tolerated guanfacine without adverse effects. The 5-day therapy regimen decreased HR, blood pressure, plasma NE and aldosterone concentrations significantly, but did not change left ventricular function, plasma BNP concentration or urinary output. Fig 2 shows the all-night profiles in HR and the HF components of HRV before and after treatment with guanfacine in a patient with dilated cardiomyopathy. Guanfacine significantly increased all spectral power, especially that of the HF components. However, a resultant decline in LF/HF did not reach statistical significance. The augmentation of HF components was accompanied by predominant overnight fluctuations that were reflected by a selective augmentation of the ultradian spectral power of HF-component variability (Fig 3) . Although average changes in spectral components did not reach statistical significance because of inter-individual variations of the baseline data, relative changes in total power, HF power, and the ultradian power of all-night HF-component variability were highly significant (Table 1) .
Discussion
In the present study night-time HRV in patients with heart failure was characterized by an attenuated ultradian rhythm of HF-components with a concomitant reduction in the averaged power of the HF-and LF-components. Lowdose guanfacine restored the nocturnal autonomic imbalance toward parasympathetic predominance over sympathetic tone in these patients. The improvement of the autonomic function was manifested by a significant augmentation of all-night HF power of HRV in association with a concomitant reduction in blood pressure, HR, and plasma NE concentration the next morning. These favorable autonomic effects of guanfacine were likely achieved through its direct action of central sympathoinhibition, not through hemodynamic improvements, because cardiac function and BNP remained unchanged. Another important finding of the present study is the augmentation of sleep ultradian power of HF-component variability with guanfacine, which suggests that the magnitude of the REM/non-REM sleep rhythm was augmented by the central sympathetic inhibition.
Effect of Low-Dose Guanfacine
A parallel decline in blood pressure and plasma NE concentration suggests that the sympathetic baroreflex function was reset toward the lower pressure range by guanfacine. These explanation is derived from the experimental evidence that 2-adrenergic agonists are known to not only suppress sympathetic activity but also to enhance baroreflex function. 17, 18 The guanfacine-induced increase in parasympathetic tone could be mediated through an improved cardiopulmonary and arterial baroreceptor function, which is frequently observed in mild to moderate congestive heart failure. 19, 20 However, an -adrenergic agonist, clonidine, is known to augment barorereflexes through the central nervous system. In the MOXICON trial, there was an excess of deaths in patients treated with 1.5 mg moxonidine, 21, 22 which exerts a central sympathoinhibitory action through stimulation of imidazoline receptors. Although that dose of moxonidine was accompanied by 52% reduction in plasma NE concentrations, 22 the actual central sympathoinhibitory effect could be more potent than reflected by the plasma NE concentration. 12 Therefore, the doses of moxonidine for some patients could have been inappropriately sympathoablative, leading to insufficient cardiac support by residual sympathetic outflow 21, 23 and progressive pump failure. We have documented previously that a small dose of guanfacine exerts sufficient but safe sympathoinhibition with augmentation of parasympathetic tone in patients with heart failure. 11, 12 Therefore, these effects of low-dose guanfacine have potential benefit to the failing heart and provide a rational basis for a novel therapeutic option for chronic heart failure.
Autonomic Function Related to Ultradian Sleep Rhythm
There have been several observations that autonomic function is synchronized with REM/non-REM ultradian sleep rhythm. [24] [25] [26] [27] Instantaneous HRV evaluated with Poincare plots documented that interbeat HRV reached the highest level in a parallel fashion with an increase in delta wave activity during non-REM sleep. 24, 27 Bonnet et al also demonstrated in normal subjects that the HRV of Stage 2 sleep containing electroencephalographic arousal resulted in a 35% reduction in HF power and an 89% increase in LF power as compared with Stage 2 without arousal. 28 These findings suggest that HRV operates as a function of sleep stage within the context of the REM/non-REM sleep cycle and arousal or sleep disturbance. In the present study, therefore, we applied spectral analysis for the first time to the HF-component variability to quantify the sleep-related ultradian rhythm of parasympathetic tone in patients with heart failure. The enhancement of the ultradian power observed after the treatment with guanfacine probably indicates that central sympathetic inhibition increased the ultradian rhythm of delta wave non-REM sleep, a finding suggestive of an improvement in sleep quality.
Study Limitations
First, this study was limited by its open-label design, the small number of patients, and the lack of placebo control. However, factors other than guanfacine could little affect the present results, if at all, because the changes in the hemodynamic and autonomic balance after guanfacine were so consistent and significant. Second, although guanfacine suppresses sympathetic nerve activity largely through its stimulation of central 2 adrenergic receptors, the present results cannot exclude the possibility that inhibition of cardiac neuronal NE release by guanfacine restored the parasympathetic tone in patients with heart failure. 29, 30 Third, we did not perform polysomnography for assessment of sleep quality, because this study was focused on the autonomic rhythmicity during sleep and the power of autonomic balancing of central sympathoinhibition. Direct comparison between the dynamics of delta wave activity and the ultradian rhythm of HF-component variability is warranted to confirm the feasibility of the ultradian rhythm derived from HRV as a marker of sleep quality. Fourth, we have not examined the reproducibility of parasympathetic oscillation related to sleep stage. This could be Circulation Journal Vol.69, September 2005 of some importance in interpreting the present results but is unlikely to be of major significance because hemodynamic, hormonal, and autonomic function showed similar directional changes with guanfacine. Finally, application of the maximum entropy method to all-night HF-component variability might result in a modest error because of the non-steady characteristics of REM/non-REM sleep cycles. Normally, slow wave oscillations with ultradian rhythm become prominent for the first 4 h of sleep and gradually decline towards the morning. To describe these sleep and autonomic profiles more precisely, spectral estimation based on the discrete wavelet transform should have been used. The wavelet distribution could provide beat-to-beat spectral analysis and illustrate transitional spectral changes within the 3-D framework of power, time, and frequency. 14, 16 
Conclusions
The present study documented that central sympathetic inhibition with an 2-aderanergic agonist, guanfacine, augmented the sleep-related ultradian rhythm of parasympathetic tone in patients with chronic heart failure. The augmentation of the parasympathetic oscillatory tone during sleep is indicative of an improvement in sleep quality in these patients. Because sleep is a continuous oscillatory process, quantitative assessment of all-night ultradian dynamics of HRV serves as a useful tool to gain insight into the pathophysiologic interaction between the sleep process and autonomic function.
